- Raised $9M A Round Extension, Aug 2023
- Raised $5M A Round Extension led by ZORA Ventures, Feb 2021
- Raised $6M Seed Extension led by iAngels, Mar 2020
About
Amai Proteins is a food technology company that develops designer proteins, primarily focusing on sweet proteins to significantly reduce added sugar in food and beverages. The company utilizes its Pro3 Platform, which combines AI-driven computational protein design, precision fermentation, and food technology. Their flagship product, Sweelin®, is a monellin-based sweet protein inspired by the serendipity berry, designed to be thousands of times sweeter than sugar, calorie-free, and stable for mass food production. Amai Proteins aims to provide a healthy, sustainable, and cost-effective sugar alternative that maintains taste and functionality, addressing global health and environmental concerns related to sugar consumption. They are also expanding into other types of proteins for meat, dairy, and plant-based alternatives.
Funding history · 12 rounds · $22.8M total
Headcount over time
Q&A
- What is Amai Proteins' primary focus?
- Amai Proteins is a food technology company that develops designer proteins, primarily focusing on sweet proteins to significantly reduce added sugar in food and beverages.
- What is the name of Amai Proteins' flagship sweet protein product?
- Amai Proteins' flagship product is Sweelin®, a monellin-based sweet protein designed to be thousands of times sweeter than sugar, calorie-free, and stable for mass food production.
- What is the status of Amai Proteins' regulatory approvals for Sweelin® in the U.S. market?
- In February 2026, Amai Proteins announced that the U.S. FDA completed its review of the GRAS (Generally Recognized as Safe) status for Sweelin®, clearing the path for accelerated U.S. commercialization.
- Has Amai Proteins received regulatory approval for Sweelin® in Asia?
- In May 2026, Amai Proteins announced that Sweelin® was approved in Singapore as a food additive by the Singapore Food Agency, expanding its regulatory footprint into Asia.
- What was a significant recent development regarding human clinical trials for Amai Proteins?
- In December 2024, Amai Proteins successfully completed the world's first human clinical trial on the effects of sweet proteins with Sweelin®.
- How many employees does Amai Proteins currently have?
- Amai Proteins has 51–200 employees.
- When did Amai Proteins secure its most recent funding round?
- Amai Proteins secured an A Round in 2026, with iAngels as a lead investor.
- What was the amount raised in Amai Proteins' A Round in December 2022?
- In December 2022, Amai Proteins raised $17,000,000 in an A Round.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | amaiproteins.com |
|---|---|
| linkedin.com/company/11406821 | |
| facebook.com/AmaiProteins | |
| YouTube | youtube.com/channel/UC7uyB19mxQd-d-uYamtVjrQ |
Identifiers & details
| Legal name | Amai Proteins Ltd. |
|---|---|
| Founded | 2016-12 |
| Employees (exact) | 125 |
Radar intelligence
Patents
| EPO | 11 |
|---|
Web history (Wayback)
| Domain | amaiproteins.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515533545 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-10-06 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 1 |
| Registry events | 6 — people (3), charge (1), other (1), shares_capital (1) |
| Registered address | הולצמן חיים 2 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-30 | עדכון דירקטורים-הוספת דירקטור |
| 2026-06-28 | רישום שעבוד |
| 2026-04-23 | שינוי בתקנון |
| 2026-04-20 | עדכון בעלי תפקידים |
| 2026-04-20 | הגדלה של הון רשום |
| 2026-05-06 | עדכון דירקטורים-הסרת דירקטור |